Last reviewed · How we verify
CCT303-406
At a glance
| Generic name | CCT303-406 |
|---|---|
| Sponsor | Shanghai PerHum Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCT303-406 CI brief — competitive landscape report
- CCT303-406 updates RSS · CI watch RSS
- Shanghai PerHum Therapeutics Co., Ltd. portfolio CI